{
    "name": "allogeneic processed thymus tissue",
    "comment": "Rx",
    "other_names": [
        "Rethymic",
        "allogeneic processed thymus tissue-agdc"
    ],
    "classes": [
        "Regenerative Therapy"
    ],
    "source": "https://reference.medscape.com/drug/rethymic-allogeneic-processed-thymus-tissue-4000006",
    "pregnancy": null,
    "lactation": null,
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "None"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Preexisting renal impairment is a risk factor for death",
                "Preexisting CMV infection may result in death before development of thymic function; benefits/risks of treatment should be considered prior to treating patients with preexisting CMV infection",
                "Because of underlying immune deficiency, patients may be at risk of posttreatment lymphoproliferative disorder"
            ],
            "specific": [
                {
                    "type": "Monitoring",
                    "description": [
                        "Monitor for development of autoimmune disorders, including complete blood cell counts with differential, liver enzymes, serum creatinine, urinalysis, and thyroid function",
                        "Monitor complete blood counts with differential weekly for first 2 months post-treatment and then monthly through 12 months post-treatment ",
                        "Liver enzymes including aspartate aminotransferase and alanine aminotransferase, serum creatinine levels, and urinalysis should be performed monthly for 3 months and then every 3 months through 12 months post-treatment ",
                        "Thyroid function studies should be performed prior to treatment and then at 6 months and 12 months post-treatment; after 12 months, testing should be performed annually ",
                        "Patients should be tested for EBV and CMV using PCR prior to and 3 months following treatment, or after any exposure to or suspected infection with CMV or EBV ",
                        "If fever develops, assess patient by blood and other cultures and treat with antimicrobials as clinically indicated "
                    ]
                },
                {
                    "type": "Graft versus host disease ",
                    "description": [
                        "Monitor and treat patients at risk of developing graft versus host disease (GVHD); risk factors include atypical complete DiGeorge anomaly phenotype, prior hematopoietic cell transplant, and maternal engraftment",
                        "Patients with elevated baseline T-cell proliferative response to phytohemagglutinin (PHA) >5,000 cpm or >20-fold over background should receive immunosuppressive therapies to decrease risk of GVHD; development of GVHD symptoms should be closely monitored and promptly treated",
                        "GVHD may manifest as fever, rash, lymphadenopathy, elevated bilirubin and liver enzymes, enteritis, and/or diarrhea"
                    ]
                },
                {
                    "type": "Infection control and immunoprophylaxis",
                    "description": [
                        "Immune reconstitution sufficient to protect from infection is unlikely to develop until 6-12 months after implantation; given the immunocompromised condition of athymic patients, follow infection control measures until the development of thymic function can be established",
                        "Maintain on immunoglobulin until all following criteria met",
                        "No longer on immunosuppression (≥10% of CD3+ T-cells are naïve in phenotype) ",
                        "≥9 months posttreatment",
                        "PHA response within normal limits",
                        "Normal serum IgA is desirable but not required",
                        "2 months after stopping immunoglobulin, IgG trough level should be checked",
                        "If IgG trough level is normal range for age, patient can remain off immunoglobulin replacement",
                        "If IgG trough level is lower than normal range for age, restart immunoglobulin replacement therapy and continue for a year before being retested using the above guidelines",
                        "Before and after treatment, maintain patient on Pneumocystis jirovecii pneumonia prophylaxis until all following criteria met",
                        "No longer on immunosuppression (≥10% of CD3+ T-cells are naïve in phenotype)",
                        "≥9 months posttreatment",
                        "PHA response within normal limits",
                        "CD4+ T-cell count >200 cells/mm",
                        "3"
                    ]
                },
                {
                    "type": "Transmission of serious infections and transmissible infections",
                    "description": [
                        "Transmission of infectious disease may occur because the implants are derived from human tissue",
                        "Screen donors for increased risk of infection with HIV, human T-cell lymphotropic virus, HBV, HCV, ",
                        "Treponema pallidum",
                        ", ",
                        "Trypanosoma cruzi",
                        ", West Nile virus, transmissible spongiform encephalopathy agents, vaccinia, and Zika virus",
                        "Screen donors screened for clinical evidence of sepsis and communicable disease risks associated with xenotransplantation (eg, CMV) "
                    ]
                },
                {
                    "type": "HLA",
                    "description": [
                        "Anti-HLA antibodies",
                        "Screen for anti-HLA antibodies before treatment",
                        "Patients testing positive for anti-HLA antibodies should receive allogeneic processed thymus tissue from a donor who does not express those HLA alleles",
                        "HLA typing",
                        "HLA matching required in patients who have received a prior hematopoietic cell transplantation (HCT) or a solid organ transplant",
                        "Patients who have received a prior HCT are at increased risk of developing GVHD after allogeneic processed thymus tissue if the HCT donor did not fully match the recipient ",
                        "Minimize this risk by HLA matching to recipient alleles that were not expressed in the HCT donor"
                    ]
                },
                {
                    "type": "Immunizations",
                    "description": [
                        "Do no administer immunizations after implantation until immune-function criteria have been met",
                        "Inactivated vaccines: May administer once all of the criteria are met",
                        "Immunosuppressive therapies have been discontinued",
                        "IgG replacement therapy has been discontinued",
                        "Total CD4+ T-cell count >200 cells/mm",
                        "3",
                        " and there are more CD4+ T cells than CD8+ T cells (CD4+ > CD8+)",
                        "Limit inactivated vaccines to 2 vaccines/month",
                        "Live vaccines",
                        "Live virus vaccines should not be administered until patients have met the criteria for inactivated vaccines and received vaccinations with inactivated agents (eg, tetanus toxoid)",
                        "No additional vaccines (live or inactivated), except the inactivated influenza vaccine, should be given within 6 months after vaccination with a measles-containing vaccine or within 2 months after the varicella vaccine",
                        "Consider verifying response to vaccination with appropriate testing, in particular varicella and measles"
                    ]
                }
            ]
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Hypertension",
            "percent": "19"
        },
        {
            "name": "Cytokine release syndrome",
            "percent": "18"
        },
        {
            "name": "Hypomagnesemia",
            "percent": "16"
        },
        {
            "name": "Rash",
            "percent": "15"
        },
        {
            "name": "Renal impairment",
            "percent": "12"
        },
        {
            "name": "failure",
            "percent": "12"
        },
        {
            "name": "Thrombocytopenia",
            "percent": "10"
        },
        {
            "name": "Graft versus host disease",
            "percent": "9"
        },
        {
            "name": "GVHD",
            "percent": "8"
        },
        {
            "name": "Neutropenia",
            "percent": "7"
        },
        {
            "name": "Respiratory distress",
            "percent": "6"
        },
        {
            "name": "Proteinuria",
            "percent": "6"
        },
        {
            "name": "Pyrexia",
            "percent": "5"
        },
        {
            "name": "Acidosis",
            "percent": "5"
        },
        {
            "name": "Diarrhea",
            "percent": null
        },
        {
            "name": "Seizure",
            "percent": null
        }
    ]
}